MBA-m1 is a reversible non-covalent allosteric inhibitor of mMLKL2 , with a K d value of 6 μM for mMLKL2 . MBA-m1 delays Necroptosis . MBA-m1 has no effect on the activities of RIPK1 or RIPK3 . MBA-m1 alleviates skin injury, epidermal thickening and immune cell infiltration in dermatitis models, and reduces aortic diameter enlargement and structural changes in abdominal aortic aneurysm models. MBA-m1 can be used in research related to dermatitis and abdominal aortic aneurysm.
Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cardiovascular Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Mixed Lineage Kinase | Products > Signaling Pathways > Necroptosis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.